Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Oct;8(10):2666-2671.
doi: 10.21037/jtd.2016.10.14.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives

Adrian Rendon  1 , Simon Tiberi  2 , Anna Scardigli  3 , Lia D'Ambrosio  4 , Rosella Centis  5 , Jose A Caminero  6 , Giovanni Battista Migliori  5
Affiliations
Editorial

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives

Adrian Rendon et al. J Thorac Dis. 2016 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This manuscript is part of the activities of the ERS/ALAT SinTB project.

Figures

Figure 1
Figure 1
Comparative analysis of the drugs included in previous classifications and in the 2016 World Health Organization (WHO) guidelines. In order to show the potentiality for upgrade of some the drugs not originally included in group 5, we have arbitrarily included in this group delamanid and bedaquiline.
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report. 2015. Available online: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
    1. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 2015;46:887-93. 10.1183/13993003.00432-2015 - DOI - PubMed
    1. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015;45:928-52. - PMC - PubMed
    1. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-20. 10.1183/09031936.00198813 - DOI - PubMed
    1. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68. 10.1183/09031936.00134712 - DOI - PMC - PubMed

Publication types

LinkOut - more resources